IMMUVANCE

Mark For: IMMUVANCE® trademark registration is intended to cover the categories of therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor; therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19. [all]

Status

2020-12-18 UTC
⟳ Refresh

LIVE APPLICATION Published for Opposition

Research	OneLook Acronym Finder
Serial Number	88751602
Registration Number	1548940
Mark Literal Elements	IMMUVANCE
Mark Drawing Type	4 - STANDARD CHARACTER MARK
Mark Type	TRADEMARK. SERVICE MARK
Register	PRINCIPAL
Current Location	INTENT TO USE SECTION 2020-09-22
Basis	1(b)
Class Status	ACTIVE
Primary US Classes	006: Chemicals and Chemical Compositions 018: Medicines and Pharmaceutical Preparations 044: Dental, Medical and Surgical Appliances 046: Foods and Ingredients of Foods 051: Cosmetics and Toilet Preparations 052: Detergents and Soaps
Primary International Class	005 - Primary Class (Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use	No
Current Use	No
Intent To Use	Yes
Filed ITU	Yes
44D Filed	No
44E Current	No
66A Current	No
Current Basis	No
No Basis	No
Attorney Name	Jared M. Barrett
Attorney Docket Number	230042.204

Timeline

IC 005. US 006 018 044 046 051 052. G & S: therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor; therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19
IC 042. US 100 101. G & S: scientific research consulting services in the field of immunology; scientific research consulting services in the field of antibodies for use in targeting the CCR5 cell receptor; scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor; medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the foregoing excluding medical research and scientific research consulting services directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting
IC 044. US 100 101. G & S: providing a website featuring medical information; providing a website featuring information in the field of antibodies for use in targeting the CCR5 cell receptor; providing health and medical information, namely, providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the forgoing excluding information directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting